FDA
-
-
-
-
-
-
-
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Sha
-
-
-
-
-
-
-
Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safe
-
-
-
-
-
-
-
Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Yea
-
-
-
-
-
-
-
Sorrento Therapeutics' (SRNEQ) Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders
-
-
-
-
-
-
-
Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.
-
-
-
-
-
-
-
Scilex (SCLX) Enters Master Distributor Agreement Among CH Trading Group and Farouk, Maamoun Tamer For Distribution of ZTlido in Kingdom of Saudi Arab
-
-
-
-
-
-
-
Sorrento Therapeutics' (SRNEQ) Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
